Hosted on MSN9mon
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
Monday, Bristol Myers Squibb & Co (NYSE:BMY) released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati (adagrasib) in combination with cetuximab for previously treated ...
pharmaphorum2y
Mirati heads for FDA verdict on KRAS drug with new data
Mirati – which is expecting a verdict on adagrasib from the FDA in December - also said the disease control rate was 80% with adagrasib, while the median duration of response came in at 8.5 ...
pharmaphorum6d
Mirati challenges Amgen with FDA okay for KRAS drug
Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...
Nature1y
KRAS deep dive yields new insights for lung cancer treatment
Nevertheless, efforts to advance KRAS as a therapeutic target began to bear fruit in the last decade, and two selective inhibitors of the KRAS-G12C oncoprotein, sotorasib and adagrasib ...